
A cheap, readily available medication that has been hailed as a wonder drug – capable of protecting against everything from diabetes to heart disease, cognitive decline and cancer.
So, what is metformin? And is there any truth to the hype?
To find out, we spoke with Dr. Greg Schwartz.
Schwartz, who has both medical and doctorate degrees, is a professor at the University of Colorado Anschutz Medical Campus and chief of cardiology at the Rocky Mountain Regional Veterans Affairs Medical Center in Aurora.
What is metformin?
Metformin is one of the most commonly used drugs on the planet, Schwartz said. More than 200 million people are estimated to be taking it across the globe every day, mostly to treat or prevent type 2 diabetes.
It’s also been around for a very long time.
“Metformin really goes back centuries,” Schwartz said. “It was used as an extract from the French lilac plant in the 1700s, and people learned that it helped to control what they called back then sweet urine disease – what we would now call diabetes,” he said.
It wasn’t until the 20th century that scientists purified the active ingredient in the botanical extract and identified it as metformin. A French physician named Jean Stern did the first tests of metformin in humans back in the 1950s and found that it helped to lower blood sugar. (For the crunchy readers who love an herbal remedy: Schwartz said you can’t substitute a botanical for a well-defined, quality-controlled pharmaceutical product containing a single active ingredient.)
“Metformin was approved for use in treating diabetes in Europe back in 1958, so we’re talking almost 70 years of use,” Schwartz said.
What does metformin do?
Metformin is broadly known to improve the way the body handles insulin, which then lowers blood sugar levels.
It’s generally well tolerated. Gastrointestinal side effects can include abdominal discomfort, decreased appetite and diarrhea, but are usually mild. Like many drugs, serious adverse effects are rare but possible, and metformin can cause a dangerous condition called lactic acidosis in fewer than 1 in 1,000 patients. That’s why research studies always examine both beneficial effects and complications of a treatment.
One study published in the Journal of Research in Medical Sciences called the adverse, or undesired, effects of the medication “negligible” when compared to the benefits.
Some studies suggest metformin may reduce the risk of blood, urologic, and gastrointestinal cancers, though results have been mixed.
What diseases does metformin treat?
Metformin has long been established as a way to treat and prevent type 2 diabetes.
Because of the way it affects insulin, metformin also can be used to treat polycystic ovary syndrome (PCOS), a hormonal disorder that can cause infertility. According to a study published in the Annals of Translational Medicine, metformin can effectively induce ovulation in some women with PCOS.
What diseases do doctors think metformin might treat?
That’s where Schwartz’s research comes in.
Metformin works by activating an enzyme called AMPK, which is essentially a sensor that regulates cellular metabolism.
“AMPK serves to protect cells against a variety of stresses,” Schwartz said. “In the liver, its activation is what’s responsible for the control of blood sugar, but in other tissues in the body, the activation of AMPK by metformin may protect those cells and increase their defense against various kinds of stressors.”
Experiments done on animals over the last two decades showed that metformin was protective in the cardiovascular system, Schwartz said. That explains why cardiologists are involved in research on a medication that is primarily used to treat diabetes.
Metformin reduced the severity of heart attacks in animals and improved blood vessel function, including the function of endothelial cells, which line blood vessels, Schwartz said. In a variety of animal species, metformin helped animals with and without diabetes live longer.
Of course, research results in animals don’t always translate to humans. Many (but not all) observations comparing people who take metformin with those who do not suggest that those who take the drug may have reduced risk of cardiovascular events, and in addition, may have lower risk of cancer and possibly even a longer lifespan, Schwartz said.
“It raises the question of whether metformin might have broader uses beyond treating blood sugar in diabetes and actually be a drug that can help protect the body in people without diabetes,” he said.
However, observations like these do not provide the highest level of clinical evidence needed to establish metformin’s role for indications beyond Type 2 diabetes.
If metformin has so many applications, why are we only finding out now?
“Metformin has been a generic drug for many, many years,” Schwartz said. “There’s not been a great deal of interest by pharmaceutical companies to test the hypothesis that metformin actually protects against things like heart attacks, strokes, and other blood vessel problems.”
In 66 years of use, Schwartz said, there hasn’t been a double-blind, randomized clinical trial – the gold standard of research to see if treatment with the drug reduces the risk of heart attacks, strokes and other heart and blood vessel problems. In such a trial, half of patients are given a treatment, such as metformin, and half are given a placebo. Neither the patients, doctors, nor the research team knows who got what treatment until the end.
Because such a trial requires the participation of many patients over a period of years, it is difficult to implement with a generic drug, Schwartz said.
“However, the U.S. Department of Veterans Affairs (VA) has undertaken that challenge, recognizing that the results may affect the treatment of many Veterans and, more broadly, many Americans,” he said.
The trial, which Schwartz is leading, has enrolled more than 3,500 patients as of November 2026 and will continue enrolling at about 40 VA medical centers across the country, including the Rocky Mountain Regional VA Medical Center. Participants have prediabetes and established cardiovascular disease, he said.
“We’re making good progress, and hopefully the trial will make an important contribution to our medical knowledge,” Schwartz said.
So, is metformin a miracle drug?
“There’s been some hype about metformin (claiming) that it’s a drug that will be the anti-aging, longevity drug that will prevent all the things that happen to us as we get older from heart disease, to cancer, to neurodegenerative disease,” Schwartz said. “And of course, if that were true, it would be fantastic. But realistically, I think we have to take it one step at a time.”
It would be premature, he said, for people to go out and start taking metformin or asking their doctor to prescribe it without the evidence to support its use outside of type 2 diabetes and a couple of specialized conditions.
How is metformin different from semaglutides like Ozempic and Wegovy?
Metformin works differently than newer GLP-1 receptor agonist drugs like semaglutide and tirzepatide, Schwartz said, though all are useful in diabetes and promote varying degrees of weight loss.
“GLP-1s are drugs with high-quality evidence for reduction of cardiovascular risk,” Schwartz said. “So, consequently, in American Diabetes Association guidelines, drugs like semaglutide have risen to the top of the recommendations for treatment in people who have diabetes and also have cardiovascular disease.”
Metformin used to be at the top of the list, Schwartz said. For now, it’s good advice to use semaglutides, he said, because they’ve been proven to work.
If Schwartz and his team can provide the same kind of high-quality evidence through their trial that metformin can do those things, metformin, which can cost less than a dollar a day, may move back up to the top of the list.
“Then we would have a drug that’s far less expensive and would provide hopefully similar benefits,” he said. “But that remains to be proven.”
Does metformin cause weight loss?
According to the Cleveland Clinic Journal of Medicine, metformin can support weight loss in adults with obesity and without type 2 diabetes, though the FDA has not approved the drug for this use because the results tend to be modest and inconsistent. Some evidence suggests metformin helps with weight loss by reducing appetite and changing the gut microbiome.